-
2 weeks ago | 
mdpi.com | Jichang Peng |Ya Gao |Lei Cai |Ming Zhang
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Oct 7, 2024 | 
jamanetwork.com | Jianguo Xu |Ya Gao |Jinhui Tian |Li Shen
Benefit of RAS Blockade in Heart Failure by Race Li Shen, MBChB, PhD; Matthew M. Y. Lee, MBChB, PhD; Pardeep S. Jhund, MBChB, MSc, PhD; Christopher B. Granger, MD; Inder S. Anand, MD, PhD; Aldo P. Maggioni, MD; Marc A. Pfeffer, MD, PhD; Scott D. Solomon, MD; Karl Swedberg, MD, PhD; Salim Yusuf, DPhil; John J. V. McMurray, MD Evaluating Tools for Assessing Bias in a Meta-Analysis of Clinical Trials on Race and RAS Blockade—Reply Li Shen, MBChB, PhD; Pardeep S. Jhund, MBChB, MSc, PhD; John J. V.
-
Sep 17, 2024 | 
nature.com | Jiangdong Liu |Jinlei Qi |Peng Yin |Wei Liu |Ya Gao |Lu Zhou | +3 more
AbstractGlobal warming shifts daytime-only heatwaves to nighttime-only and day–night compound heatwaves. However, evidence on the cause-specific burdens of these heatwaves in a changing climate and ageing population is limited.
-
Aug 24, 2024 | 
thelancet.com | Ya Gao |Gordon Guyatt |Timothy M. Uyeki |Ming Liu
Research in contextEvidence before this studyAntivirals are frequently used in the clinical management of people with severe influenza. Previous systematic reviews and meta-analyses have reported that early initiation of neuraminidase inhibitor treatment in hospitalised patients with influenza might be associated with reduced mortality and length of hospital stay compared with later or no neuraminidase inhibitor treatment.
-
Aug 2, 2024 | 
studyfinds.org | Ya Gao |Peng Yin
(Photo by Jamie Street on Unsplash)SHANGHAI, China — The ups and downs of the stock market may be doing more than just affecting your wallet – they could be impacting your health in serious ways. A new study out of Fudan University in China shows a troubling link between stock market volatility and increased risks of heart attacks, strokes, and even suicide. The research, published in the journal Engineering, analyzed over 12 million deaths in China between 2013 and 2019.
-
Jun 28, 2024 | 
jamanetwork.com | Ya Gao |Lin Lin |Peng Yin |Haidong Kan
Key PointsQuestion Do nighttime and daytime heat exposure differ in their association with dementia-related deaths? Findings In this case-crossover study of 132 573 dementia-related deaths, immediate and significant risk was associated with both nighttime and daytime heat. Stricter thresholds for nighttime heat were associated with a higher burden of dementia-related deaths compared with daytime heat.
-
Jun 17, 2024 | 
einnews.com | Ya Gao
FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis-a Chronic Rare Disease in Nephrology -- The United States FDA Clears Initiation of Efficacy Trial in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) Patients CLEVELAND, OHIO, UNITED STATES, June 17, 2024 /EINPresswire.com/ -- NovelMed proudly announces the U.S. Food and Drug Administration's (FDA) clearance on Ruxoprubart, the investigational drug, for commencing an efficacy trial...
-
Apr 15, 2024 | 
einnews.com | Ya Gao
The United States FDA Awards Orphan Drug Designation (ODD) to NM5072 for Treating Paroxysmal Nocturnal Hemoglobinuria CLEVELAND, OHIO, UNITED STATES, April 15, 2024 /EINPresswire.com/ -- NovelMed today announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to NM5072, an AP blocker anti-Properdin antibody, for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) (www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=835921).
-
Feb 12, 2024 | 
einnews.com | Ya Gao
Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment! CLEVELAND, OHIO, UNITED STATES, February 12, 2024 /EINPresswire.com/ -- NovelMed today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ruxoprubart, an alternative pathway (AP) blocker anti-Bb antibody, for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)...
-
Feb 8, 2024 | 
mdpi.com | Ya Gao
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticleby 1 and 2,* 1School of Public Finance and Taxation, Central University of Finance and Economics, Beijing 100081, China2China Center for Information Industry Development, Beijing 100048, China*Author to whom correspondence should be addressed.
